Robert Glassman Sells 8,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 8,000 shares of Pharvaris stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $37.55, for a total value of $300,400.00. Following the transaction, the director owned 10,500 shares of the company’s stock, valued at $394,275. The trade was a 43.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Pharvaris Stock Up 1.4%

Shares of PHVS stock opened at $38.02 on Friday. Pharvaris N.V. has a 52-week low of $20.65 and a 52-week high of $43.25. The stock has a market cap of $2.49 billion, a PE ratio of -12.47 and a beta of -2.33. The business has a 50-day simple moving average of $35.09 and a 200-day simple moving average of $31.38.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Sell-side analysts anticipate that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Institutional Trading of Pharvaris

Institutional investors and hedge funds have recently modified their holdings of the stock. Alyeska Investment Group L.P. boosted its stake in shares of Pharvaris by 225.5% in the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock worth $14,068,000 after acquiring an additional 281,829 shares during the last quarter. Seven Fleet Capital Management LP increased its position in shares of Pharvaris by 472.3% during the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock worth $8,947,000 after purchasing an additional 261,355 shares in the last quarter. BlackRock Inc. acquired a new position in Pharvaris in the 2nd quarter valued at $26,677,000. PSP Research LLC acquired a new position in Pharvaris in the 4th quarter valued at $569,000. Finally, DV Trading LLC purchased a new position in Pharvaris in the 1st quarter valued at $4,067,000.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris reported that once-daily extended-release deucrictibant reduced HAE attack rates by 83% versus placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a p-value below 0.0001, and the study met its primary and secondary efficacy endpoints. The company plans to begin regulatory submissions in the first half of 2027. Pharvaris CHAPTER-3 topline data
• Positive Sentiment: The results strengthen Pharvaris’ potential to offer convenient oral treatments for both HAE prevention and acute attacks. Analysts believe the data could help the company gain market share in the HAE market. Pharvaris HAE market-share analysis
• Positive Sentiment: Analyst sentiment remains broadly favorable. Leerink Partners reiterated a Buy/Outperform view, while RBC Capital raised its price target to $62, Citizens JMP increased its target to $79, and HC Wainwright maintained a Buy rating with a $60 target. These revisions imply substantial upside from recent trading levels.
• Neutral Sentiment: Pharvaris is still a clinical-stage biotechnology company. Regulatory approval, launch execution, competition from established HAE therapies and continued cash requirements remain key risks. The company also recently reported a quarterly loss that was larger than analysts expected.
• Negative Sentiment: Director Robert Glassman sold 8,000 shares for approximately $300,400, reducing his direct holdings by 43.24%. President Peng Lu also sold 15,000 shares worth about $610,200, cutting his ownership by 18.71%. The insider selling may create a modest sentiment overhang, although it does not alter the favorable clinical results.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. UBS Group set a $79.00 price objective on shares of Pharvaris in a report on Wednesday. Citizens Jmp increased their target price on shares of Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Citigroup restated a “market outperform” rating on shares of Pharvaris in a research report on Wednesday. Rosenblatt Securities set a $60.00 price target on Pharvaris in a report on Wednesday. Finally, Royal Bank Of Canada increased their price target on Pharvaris from $52.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.50.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.